Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
RC

NASDAQ · RCEL

AVITA Medical, Inc.

Healthcare · Medical - Devices

$9.86

Down-$0.30 (-2.95%)

Updated Sep 11, 2026, 4:01 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
94.53M
P/E ratio
-1.8
Dividend yield
0.00%
52-week range
$3.22 – $11.39
Volume
245.4K
Avg. volume
574.48K

Price performance

RCEL price history

1M range · 20 trading sessions · Daily adjusted prices

RCEL closed at $9.86 after 20 trading sessions, up 23.10% for the selected period.

Last close
$9.86
Period change
+23.10%
Period low
$7.85
Period high
$11.20
Daily close
View OHLC price history
RCEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$10.00$10.34$9.80$9.86245.4K
Sep 9, 2026$10.32$10.495$10.11$10.16154.5K
Sep 8, 2026$11.23$11.23$10.33$10.41312.05K
Sep 4, 2026$10.99$11.39$10.80$11.20301.85K
Sep 3, 2026$10.90$11.20$10.70$10.94320.14K
Sep 2, 2026$10.10$10.87$10.065$10.76542.59K
Sep 1, 2026$10.02$10.29$9.97$10.07142.65K
Aug 31, 2026$10.26$10.29$9.84$10.10182.77K
Aug 28, 2026$10.48$10.65$10.15$10.35203.88K
Aug 27, 2026$10.41$10.5282$10.1411$10.32254.25K
Aug 26, 2026$10.53$10.71$10.14$10.59287.84K
Aug 25, 2026$10.04$10.77$9.93$10.50452.19K
Aug 24, 2026$10.09$10.22$9.66$9.91222.28K
Aug 21, 2026$10.30$10.39$9.9158$10.06301.36K
Aug 20, 2026$10.15$10.34$9.89$10.09413.51K
Aug 19, 2026$9.83$10.415$9.25$10.34789.2K
Aug 18, 2026$7.94$10.20$7.72$9.851.43M
Aug 17, 2026$7.91$8.15$7.74$7.90194.16K
Aug 14, 2026$8.01$8.17$7.66$7.85270.99K
Aug 13, 2026$8.08$8.55$7.94$8.01404.03K

Latest RCEL news

The latest Smart Investors Daily articles mentioning RCEL.

Stock researchCompany · Overview

RCEL research

Overview

Company profile and research snapshot.

Company profile

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
RCEL recent ratings
DateFirmRatingTarget
Aug 28, 2026Lake StreetBuy—
Aug 19, 2026BTIGBuy—
Aug 19, 2026TD CowenBuy—
Aug 7, 2026BTIGBuy—
May 15, 2026Lake StreetBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 25, 2026

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By